Skip To Main Content
Fabrice Barlesi on Muck Rack

Fabrice Barlesi

As seen in: Nature, Wiley Online Library, Therapeutic Advances in Medical Oncology, Medscape, The Lancet, Cell Press, medRxiv, European Respiratory Journal, Targeted Oncology, International Journal of Radiation Oncology*Biology*Physics and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Fabrice

Contact Fabrice, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Circulating epigenetic and epitranscriptomic biomarkers identify EGFR status, predict TKI response and reveal therapeutic vulnerabilities in NSCLC

|
By Judith Raimbourg, Gwenola Bougras-Cartron, Arulraj Nadaradjane, Fabien Gautier, Julien Mazieres, Olivier Molinier, Fabrice Barlesi, Pierre-François Cartron, Dorian Espi-Bastien, Séverine Blondeau, Guillaume Dupas, Bertrand Volard, Armelle Lefrançois, Franck Morin, Elodie Amour, Mathilde Dupé
| Nature Verified
Abstract Circulating cell-free epigenetic and epitranscriptomic modifications (epimarks) are emerging as minimally invasive biomarkers for cancer detection and therapeutic monitoring. Their clinical utility in non-small cell lung cancer (NSCLC), particularly in the context of EGFR-targeted therapies, remains to be fully established.
Open in Who Shared Issue with article?

Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers study

|
By Fabrice Barlesi, Fréderic Vély, Florence Monville
| medRxiv
The authors have declared no competing interest. This work benefited from a government grant handled by the French National Research Agency (ANR) as part of the France 2030 investment plan, under the reference ANR-17-RHUS-0007.
Open in Who Shared Issue with article?

Mapping the antibody-drug‐conjugates landscape in non-small cell lung cancer: Where are we and where are we going?

|
By Claudia Parisi, Fabrice Barlesi, David Planchard
| Wiley Online Library Verified
Open in Who Shared Issue with article?
See all 31 licensed articles (32 Total)